FDA clears J&J’s Icotyde for plaque psoriasis

Johnson & Johnson said the US FDA has approved Icotyde, the brand name for icotrokinra, for moderate-to-severe plaque psoriasis in adults and in pediatric patients age 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The March 18 approval gives J&J what it describes as the first oral IL-23 pathway medicine for this use, expanding competition in a psoriasis market that has been dominated by injectables and, among oral agents, TYK2 and PDE4 inhibitors. The approval follows J&J’s Phase 3 ICONIC program and comes as Takeda is also advancing an oral psoriasis contender, zasocitinib, with new late-breaking Phase 3 data presented at AAD 2026. (investor.jnj.com)

Why it matters: For veterinary professionals tracking human drug regulation as a signal for broader immunology and dermatology innovation, Icotyde is notable because it brings a new oral mechanism, selective IL-23 receptor blockade, into a high-volume chronic inflammatory disease category. That could sharpen attention on oral, targeted peptide approaches, adherence advantages versus injectables, and future spillover into adjacent immune-mediated indications and platform technologies that may eventually influence animal health R&D thinking, even though this approval is strictly for human medicine. (investor.jnj.com)

What to watch: Next will be launch execution, payer access, uptake against established biologics and oral competitors, and whether additional icotrokinra data in psoriasis, psoriatic arthritis, and ulcerative colitis broaden the product’s role. (investor.jnj.com)